Residual solvents in peptide powder: reading a GC report before purchase

Start with the solvents relevant to the actual manufacturing route and the agreed purchasing specification. Ask the supplier to identify which solvents were used, which could remain and which are covered by the report. A heading such as "residual solvents: conforms" leaves the buyer unable to check the analytical scope. ICH Q3C describes gas chromatography as a typical technique for this purpose.

For a cosmetic peptide freeze-dried powder enquiry, request a solvent-by-solvent record alongside the material code and batch number. If a supplier offers a standard testing panel, compare that panel with its process declaration. Record any gap for technical review before placing the order. This is a suggested purchasing workflow; it does not imply that every peptide uses the same solvents. A supplier's confidential process can be discussed through an agreed disclosure arrangement without replacing the report with an unsupported assurance.

Treat an ICH number as a pharmaceutical reference until its relevance to the cosmetic project has been assessed. Q3C(R9) gives acetonitrile a permitted daily exposure of 4.1 mg/day and an Option 1 concentration limit of 410 ppm. Option 1 uses a 10 g daily product intake assumption. Its Class 3 discussion gives 5000 ppm, or 0.5%, under Option 1. These are not universal cosmetic ingredient limits.

Put the intended cosmetic application, ingredient concentration and destination market in the specification review. Ask the responsible safety assessor or quality specialist to document the acceptance basis. Copying a pharmaceutical table into a purchase order can conceal a mismatch between the exposure assumptions and the actual use. The purchase file should distinguish the reference consulted from the limit approved for that material. Do not describe a powder as FDA approved or ICH certified merely because a report cites this guideline.

Ask the laboratory to define "ND" and provide the numerical threshold behind it. A detection limit concerns detection; a quantitation limit concerns reliable quantification. ICH Q2(R2) treats these as separate analytical characteristics. A result reported below a threshold does not establish that the solvent concentration is zero.

Consider a hypothetical purchase limit of 100 ppm. A report saying only "below 200 ppm" cannot establish compliance with that limit, because the reported interval includes concentrations above 100 ppm. The appropriate next step is a method-suitability discussion with the laboratory, followed by the agreed testing and decision process. The example uses invented values to explain reporting resolution, not a recommended solvent limit. Keep the original wording in the receiving record. Replacing "less than" with zero in a spreadsheet changes the meaning of the laboratory result and can distort later comparisons between suppliers.

Keep the shipment decision open until the missing information has a documented owner and resolution. For example, if a report lists ethanol but the process declaration also identifies acetonitrile, ask whether acetonitrile was tested, controlled elsewhere or omitted. Do not infer the answer from the peptide's HPLC purity percentage. Request the evidence that addresses the named solvent.

A useful review record contains the supplier's original report, the buyer's question and the laboratory's clarification in one place. If further testing is agreed, specify the retained sample or unopened unit to be used and the acceptance rule before the result arrives. Then record the authorized disposition. For future orders, put the resolved requirement into the approved specification revision so the same ambiguity does not recur. This checklist supports procurement review; it does not prescribe a manufacturing process or promise a particular residual-solvent level.